Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: A previously unknown adverse event [2]

Annals of Oncology

Volumn 8, Issue 9, 1997, Pages 919-920

  Lebrun, C ^a   Chichmanian, R M ^a   Peyrade, F ^a   Chatel, M ^a   Frenay, M ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ RECEPTOR AGONIST; CARBAMAZEPINE; CARBOPLATIN; LOBRADIMIL; LOMUSTINE; METHYLPREDNISOLONE; ONDANSETRON; PHENYTOIN; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; VIGABATRIN; VINCRISTINE;

ADULT; ASTROCYTOMA; CASE REPORT; EPILEPSY; HUMAN; INTESTINE OBSTRUCTION; INTRACRANIAL HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LETTER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

EID: 0030882483     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008205308867     Document Type: Letter

References (5)

1. R.T. Bartus P.J. Elliott N.J. Hayward The bradykinin B2 agonist, RMP-7: A novel means of increasing delivery of chemo-therapeutic agents to gliomas J Neuro Oncol 30 2 1996 97
2. A. Dubois H.G. Meerpohl W. Vach Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: A study with ondansetron Eur J Cancer 28 2–3 1992 450 457
3. A.L. Finn Toxicity and side effects of ondansetron Semin Oncol 18 4 1992 53 60
4. N.J. Talley S.F. Phillips L.J. Miller Specific 5-HT3 receptor antagonist (GR38032) slows colonic transit and reduces neurotensin (NT) response in man Gut 29 1988 1480
5. S. Gore I.T. Gilmore C.G. Haigh Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist Aliment Pharmacol Ther 4 1990 139 144